NCT04211181 CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism
| NCT ID | NCT04211181 |
| Status | Recruiting |
| Phase | — |
| Sponsor | China-Japan Friendship Hospital |
| Condition | Venous Thromboembolic Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 5,800 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 5,800 participants in total. It began in 2025-08-01 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Although pharmacologic and mechanical methods to prevent VTE are safe, effective, cost-effective, and advocated by authoritative guidelines,many studies continue to demonstrate that these preventive methods are significantly underutilized, especially in China.A number of quality improvements (QI) program have been established in several countries or hospitals.However,no exit effective protocol has been demonstrated well enough or adequate to drive breakthrough levels of improvement. A reliable and practical QI that can support hospitals or physicians in China is warranted.To evaluate the multifaceted quality improvement intervention effect in clinical setting, we will conduct a cluster-randomized clinical trial among China PUlmonary Thromboembolism REgistry Study (CURES) group, aiming to test whether it's applicable to real-world practice in China. A multicenter, two-arms, open-label clinical trial has been designed to determine whether the system-wide multifaceted intervention could increase the rate of at-risk participants who received prophylaxis (RP) and decrease the incidence of any hospital-associated VTE in 90 days during and after hospital admission. .Selected hospital will be regarded as a cluster and randomized into interventional or control group.In interventional group, eligible hospitalized patients will receive a variety of the multifaceted quality improvement(QI) interventions since admitted in hospital.In control group, patients will receive no more than common recommended care or an existing policy.The primary outcomes are the proportion of appropriate prophylaxis in hospitalized patients and the incidence of HA-VTE in 90 days after hospital admission.
Eligibility Criteria
Inclusion Criteria: 1. Aged ≥14 years 2. Have an expected hospital stay ≥72 hours for medical and/or surgical treatment 3. Written informed consent Exclusion Criteria: 1. Inability to be followed-up at until 3 months after randomization 2. Have participated in similar trials or are undergoing other clinical trials 3. Refuse or are unable to give informed consent 4. VTE identified on CTPA or lower extremity vein ultrasound at or any time before enrollment 5. Requiring a full dose of anticoagulant treatment (e.g., recent VTE, atrial fibrillation).
Contact & Investigator
Zhenguo Zhai, Doctor
PRINCIPAL INVESTIGATOR
China-Japan Friendship Hospital
Frequently Asked Questions
Who can join the NCT04211181 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, studying Venous Thromboembolic Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04211181 currently recruiting?
Yes, NCT04211181 is actively recruiting participants. Contact the research team at zhaizhenguo2011@126.com for enrollment information.
Where is the NCT04211181 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT04211181 clinical trial?
NCT04211181 is sponsored by China-Japan Friendship Hospital. The principal investigator is Zhenguo Zhai, Doctor at China-Japan Friendship Hospital. The trial plans to enroll 5,800 participants.